From CRISPR-CAS9 drop-out screens to novel therapeutic approaches in acute myeloid leukaemia

Acute myeloid leukaemia (AML) is a devastating disease with a long-term survival of less than 30%. The study of its molecular pathogenesis through rational mechanistic studies has been at the center of efforts to identify novel therapeutic approaches against the disease, and these efforts have accelerated dramatically in recent years, propelled in part by advances in cancer genomics. Despite such progress cytarabine, developed more than 50 years ago, represents the last major addition to mainstream anti-AML therapy.

Source: Experimental Hematology - August 22, 2017 Category: Hematology Authors: George Vassiliou Source Type: research